- Home
- LENZ vs COLL Comparison
LENZ vs COLL Comparison
Compare LENZ & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- COLL
- Stock Information
- Founded
- LENZ 2019
- COLL 2002
- Country
- LENZ United States
- COLL United States
- Employees
- LENZ N/A
- COLL N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- COLL Health Care
- Exchange
- LENZ Nasdaq
- COLL Nasdaq
- Market Cap
- LENZ 1.1B
- COLL 958.8M
- IPO Year
- LENZ 2021
- COLL 2015
- Fundamental
- Price
- LENZ $41.98
- COLL $38.32
- Analyst Decision
- LENZ Strong Buy
- COLL Strong Buy
- Analyst Count
- LENZ 4
- COLL 4
- Target Price
- LENZ $49.75
- COLL $44.25
- AVG Volume (30 Days)
- LENZ 706.3K
- COLL 445.8K
- Earning Date
- LENZ 11-05-2025
- COLL 11-06-2025
- Dividend Yield
- LENZ N/A
- COLL N/A
- EPS Growth
- LENZ N/A
- COLL N/A
- EPS
- LENZ N/A
- COLL 1.06
- Revenue
- LENZ $5,000,000.00
- COLL $707,007,000.00
- Revenue This Year
- LENZ N/A
- COLL $22.23
- Revenue Next Year
- LENZ $258.37
- COLL $2.78
- P/E Ratio
- LENZ N/A
- COLL $36.19
- Revenue Growth
- LENZ N/A
- COLL 22.61
- 52 Week Low
- LENZ $16.54
- COLL $23.23
- 52 Week High
- LENZ $42.08
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- LENZ 66.44
- COLL 59.51
- Support Level
- LENZ $36.81
- COLL $38.00
- Resistance Level
- LENZ $40.35
- COLL $39.78
- Average True Range (ATR)
- LENZ 1.84
- COLL 0.97
- MACD
- LENZ 0.04
- COLL -0.18
- Stochastic Oscillator
- LENZ 98.27
- COLL 38.72
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.